Prelude Therapeutics (PRLD) Competitors $1.30 +0.41 (+46.40%) (As of 12/20/2024 05:40 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends PRLD vs. LYEL, OPT, GNFT, ALEC, GOSS, AMRN, KYTX, MDWD, HURA, and SGMTShould you be buying Prelude Therapeutics stock or one of its competitors? The main competitors of Prelude Therapeutics include Lyell Immunopharma (LYEL), Opthea (OPT), Genfit (GNFT), Alector (ALEC), Gossamer Bio (GOSS), Amarin (AMRN), Kyverna Therapeutics (KYTX), MediWound (MDWD), TuHURA Biosciences (HURA), and Sagimet Biosciences (SGMT). These companies are all part of the "pharmaceutical products" industry. Prelude Therapeutics vs. Lyell Immunopharma Opthea Genfit Alector Gossamer Bio Amarin Kyverna Therapeutics MediWound TuHURA Biosciences Sagimet Biosciences Lyell Immunopharma (NASDAQ:LYEL) and Prelude Therapeutics (NASDAQ:PRLD) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability, analyst recommendations, media sentiment and community ranking. Does the media favor LYEL or PRLD? In the previous week, Prelude Therapeutics had 5 more articles in the media than Lyell Immunopharma. MarketBeat recorded 6 mentions for Prelude Therapeutics and 1 mentions for Lyell Immunopharma. Prelude Therapeutics' average media sentiment score of 1.69 beat Lyell Immunopharma's score of 0.84 indicating that Prelude Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lyell Immunopharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Prelude Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Do analysts rate LYEL or PRLD? Lyell Immunopharma presently has a consensus price target of $1.00, indicating a potential upside of 63.21%. Prelude Therapeutics has a consensus price target of $4.00, indicating a potential upside of 207.69%. Given Prelude Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Prelude Therapeutics is more favorable than Lyell Immunopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lyell Immunopharma 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50Prelude Therapeutics 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Does the MarketBeat Community favor LYEL or PRLD? Prelude Therapeutics received 16 more outperform votes than Lyell Immunopharma when rated by MarketBeat users. Likewise, 49.18% of users gave Prelude Therapeutics an outperform vote while only 48.28% of users gave Lyell Immunopharma an outperform vote. CompanyUnderperformOutperformLyell ImmunopharmaOutperform Votes1448.28% Underperform Votes1551.72% Prelude TherapeuticsOutperform Votes3049.18% Underperform Votes3150.82% Which has better valuation and earnings, LYEL or PRLD? Prelude Therapeutics has higher revenue and earnings than Lyell Immunopharma. Lyell Immunopharma is trading at a lower price-to-earnings ratio than Prelude Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLyell Immunopharma$63K2,841.39-$234.63M-$0.79-0.78Prelude Therapeutics$3M23.85-$121.83M-$1.78-0.73 Is LYEL or PRLD more profitable? Prelude Therapeutics has a net margin of 0.00% compared to Lyell Immunopharma's net margin of -323,792.09%. Lyell Immunopharma's return on equity of -34.64% beat Prelude Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Lyell Immunopharma-323,792.09% -34.64% -30.02% Prelude Therapeutics N/A -66.89%-55.59% Which has more volatility and risk, LYEL or PRLD? Lyell Immunopharma has a beta of -0.45, suggesting that its share price is 145% less volatile than the S&P 500. Comparatively, Prelude Therapeutics has a beta of 1.49, suggesting that its share price is 49% more volatile than the S&P 500. Do institutionals & insiders hold more shares of LYEL or PRLD? 66.1% of Lyell Immunopharma shares are held by institutional investors. Comparatively, 79.7% of Prelude Therapeutics shares are held by institutional investors. 25.1% of Lyell Immunopharma shares are held by company insiders. Comparatively, 62.8% of Prelude Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. SummaryPrelude Therapeutics beats Lyell Immunopharma on 14 of the 18 factors compared between the two stocks. Ad WealthPressYour chance to get on the next “60-Second Trade”Ever heard of the “60-Second Trade”? It’s a unique cash flow strategy that lets regular traders target anywhere from $100 to a couple of thousand in extra cash flow in as little as 7 days… In on Monday, out on Friday!Just head over here! Get Prelude Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PRLD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRLD vs. The Competition Export to ExcelMetricPrelude TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$71.55M$6.57B$5.12B$9.07BDividend YieldN/A2.98%4.91%4.22%P/E Ratio-0.7310.5991.3417.19Price / Sales23.85195.381,116.59116.80Price / CashN/A57.1642.6437.86Price / Book0.305.104.794.78Net Income-$121.83M$151.51M$120.07M$225.60M7 Day Performance62.50%-2.15%-1.89%-1.24%1 Month Performance34.41%-3.14%11.45%3.36%1 Year Performance-67.98%11.50%30.61%16.58% Prelude Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRLDPrelude Therapeutics2.9348 of 5 stars$1.30+46.4%$4.00+207.7%-67.3%$71.55M$3M-0.73120News CoveragePositive NewsGap UpHigh Trading VolumeLYELLyell Immunopharma2.2251 of 5 stars$0.66-2.0%$1.00+51.4%-69.1%$192.92M$63,000.00-0.85270Gap DownOPTOpthea2.5742 of 5 stars$3.30+1.5%$12.00+263.6%+31.5%$192.70M$124,666.000.008Analyst UpgradeNews CoverageGNFTGenfit1.1979 of 5 stars$3.85+0.8%$13.00+237.7%+2.2%$192.46M$41.31M0.00120Positive NewsALECAlector4.2493 of 5 stars$1.96-0.5%$4.00+104.1%-76.4%$191.95M$61.51M-1.16270Analyst DowngradeGOSSGossamer Bio3.622 of 5 stars$0.84-9.6%$9.20+994.5%-1.4%$190.48M$105.32M-2.61180AMRNAmarin0.0303 of 5 stars$0.46+1.8%N/A-42.6%$190.35M$241.02M-5.06360Analyst ForecastKYTXKyverna Therapeutics2.4246 of 5 stars$4.36-1.4%$25.71+489.8%N/A$188.23M$7.03M0.0096News CoverageMDWDMediWound1.9106 of 5 stars$17.40+0.6%$27.50+58.0%+58.3%$187.68M$19.72M-5.9380Positive NewsGap DownHURATuHURA BiosciencesN/A$4.35-11.8%$15.00+244.8%N/A$183.94MN/A0.00N/AAnalyst ForecastNews CoverageSGMTSagimet Biosciences2.3237 of 5 stars$5.97+36.0%$23.00+285.3%-8.0%$183.10M$2M0.008Gap UpHigh Trading Volume Related Companies and Tools Related Companies Lyell Immunopharma Alternatives Opthea Alternatives Genfit Alternatives Alector Alternatives Gossamer Bio Alternatives Amarin Alternatives Kyverna Therapeutics Alternatives MediWound Alternatives TuHURA Biosciences Alternatives Sagimet Biosciences Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:PRLD) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prelude Therapeutics Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Prelude Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PRLD Stock Alerts